Recent Updates
Recently added Catalysts

Upcoming Catalyst

Drug Pipeline Intelligence

Clinical Trial Results

Inside Trades

Options Data

News Section

Hedge Funds

Ownership Trends

Competitive Position

Perceptive Capital Solutions Corp Class A Ordinary Shares

$10.91

-0.1 (-0.91%)

Market Cap
97.67 M
EPS
0.08
P/E Ratio
144.78 $
Value Trade
8.02 M
SEC Financials
Q4 2025

  • Dilution Risk

    25%

  • Operating CF

    -216.00 K

  • Total Assets

    92.78 M

  • Total Liabilities

    5.70 M

  • Equity

    -4.80 M

  • D/E Ratio

    12,345

%
Week
%
1 Month
%
3 Month
%
6 Month
%
5 Year
%
All Time
Cash Data
Stable

  • Cash Position

    865.03 K

  • Monthly Burn

    72.00 K

  • Runway

    12 mo

  • Burn Trend

    Decelerating

  • SEC Filing

    Mar 12, 2026
Overview
Volume
116.14 K
52 Week Range
10.28 - 14.47
% held by Insiders
28.85 %
% held by Institutions
98.21 %
Enterprise Value
96.80 M
Total Shares
8.91 M
Short %
8.64 %
Float Shares
8.62 M
Company Description
HQ: 51 ASTOR PLACE, 10TH FLOOR, NE...

locked

Upcoming Catalyst
Catalyst Drug/Treatment Stage Probability of Approval Description Drug Type Therapeutic Area Source
PDUFA 2026
Example Drug Treatment for example condition requiring FDA review
Phase 3
-%
Small Molecule
Oncology
Example Drug Treatment for example condition requiring FDA review
Phase 3
-%
Small Molecule
Oncology
Example Drug Treatment for example condition requiring FDA review
Phase 3
-%
Small Molecule
Oncology
Unlock Upcoming Catalyst data
Drug Pipeline Intelligence
Unlock Drug Pipeline Intelligence
Clinical Trial Results
Drug Name Indications Phase Date Trial Results Summary Title Source
Example Drug
Example indication for clinical evaluation
Phase 3
2025-12-01
Example Drug
Example indication for clinical evaluation
Phase 3
2025-12-01
Example Drug
Example indication for clinical evaluation
Phase 3
2025-12-01
Unlock Clinical Trial Results data
Inside Trades
TREND
CORPORATE INSIDERS BOUGHT SHARES WORTH 1.8M IN THE LAST 3 MONTHS
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Unlock Inside Trades data
Show Data
Hedge Funds
TREND
HEDGE FUNDS INCREASED HOLDINGS BY 200.0K SHARES IN THE LAST QUARTER
Shares Held
2040.00B1530.00B1020.00B510.00B0
Q3
2024
Q4
2024
Q1
2025
Q2
2025
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Fund Count
60%
Share Volume
25%
Conviction
15%
Hedge Funds invested in PCSC
HedgeFund Name
( 3 )
% of Portfolio Current MV
-
Shares Owned
-
Activity
Avg Price $0

Example Capital Management

2.5 %
15.00 M
250.00 K

Example Capital Management

2.5 %
15.00 M
250.00 K

Example Capital Management

2.5 %
15.00 M
250.00 K
Unlock Hedge Funds table data
Perceptive Capital Solutions Corp Class A Ordinary Shares (PCSC) Analyst Ratings & Price Targets
Symbol
Firm
Rating
Action
Price Target
Upside
date
PCSC
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
PCSC
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
PCSC
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
Unlock Biotech Analyst Ratings data
PCSC Stock Forecast & Analyst Consensus
BUY
Analyst Ratings
Buy65.0%
Hold25.0%
Sell10.0%
Price Target Trend
Average$24.00
Low$18.00
High$32.00
Unlock Price Target Trend
PCSC Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
ExpirationVolumeOpen InterestImplied Volatility CallsImplied Volatility Puts
CallsPutsPut-Call RatioCallsPutsPut-Call RatioIVOiWaIvVWaIvIVOiWaIvVWaIv
Unlock Option Chain Statistics data
Option Chain
CallsStrikePuts
Last PriceVolumeOpen InterestLast PriceVolumeOpen Interest
No data available
Unlock Option Chain data
Unlock Options Chart data
Open interest
0 600K 1.2M 1.8M Avg OI 1.00 M Open Interest
0 1 2 3 1.1 Put-Call Ratio
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
0 450K 900K 1.4M Avg OV 750.00 K Option Volume
0 1 2 3 0.95 Put-Call Ratio
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
-PCSC
Jun 18, 2026
PCSCGeneral

Perceptive Capital Solutions Corp and Freenome Announce Effectiveness of Registration Statement for Proposed Business Combination - Extraordinary General Meeting of Perceptive Shareholders Scheduled for

Perceptive Capital Solutions Corp (PCSC) and Freenome Holdings, Inc. have announced that their registration statement for a business combination has been declared effective by the SEC as of June 17, 2026. An extraordinary general meeting for PCSC shareholders is scheduled for July 9, 2026, to vote on the proposed merger. Upon successful closure of the transaction, which is anticipated in July 2026, PCSC will be renamed Freenome, Inc. Freenome focuses on developing blood-based tests for early cancer detection.

Read more →
-PCSC
Dec 5, 2025
PCSCGeneral

Freenome and Perceptive Capital Solutions Corp Announce Business Combination Agreement to Create a Publicly Listed Company Transforming Blood-Based Multi-Cancer Detection through an AI/ML-Enabled Multiomics Platform - Le

Freenome Holdings, Inc. and Perceptive Capital Solutions Corp have announced a business combination agreement that will lead to Freenome becoming publicly listed on Nasdaq under the ticker FRNM. This partnership aims to enhance blood-based multi-cancer detection using an advanced AI/ML-enabled multiomics platform. The deal is expected to close in the first half of 2026 and includes a substantial $240 million in private investment from notable healthcare investors. Freenome's proven technology in early cancer detection positions it well for commercialization and growth in the upcoming years.

Read more →
-PCSC
Aug 8, 2024
PCSCGeneral

INDEX TO FINANCIAL STATEMENT Page Balance Sheet of Perceptive Capital Solutions Corp: Report of Independent Registered Public Accounting Firm F-2 Balance Sheet F-3 Notes to Financial Statement F-4 F-1 REPORT OF INDEPENDE

Perceptive Capital Solutions Corp has published its audited balance sheet as of June 13, 2024. The audit report states that the financial statement fairly represents the company's financial condition, highlighting total assets of approximately $88.2 million. The company recently completed an Initial Public Offering, raising $86.25 million, but has yet to commence operations or generate revenues. Future success depends on the ability to execute a Business Combination, which currently has no guaranteed outcome.

Read more →
-PCSC
Jun 12, 2024
PCSCGeneral

Perceptive Capital Solutions Corp Announces Pricing of $75 Million Initial Public Offering

Perceptive Capital Solutions Corp has announced the pricing of its initial public offering at $75 million, with Class A ordinary shares priced at $10.00 each. The shares are set to begin trading on Nasdaq under the ticker symbol 'PCSC'. The company, which is a special purpose acquisition company, aims to invest primarily in the healthcare sector in the U.S. and other developed nations. The offering is expected to close on June 13, 2024, subject to customary conditions.

Read more →
Competitive Position
How PCSC ranks across every disease it competes in
Competitive Position is a premium feature
See how PCSC ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial